Nia Tatsis, Ph.D., joined Vertex in 2017 and is the company’s Executive Vice President and Chief Regulatory and Quality Officer. In this role, she provides global regulatory leadership and is responsible for managing all regulatory interactions and quality assurance involving the research and development, manufacturing, and commercialization of Vertex’s transformational medicines. In addition to creating and executing the company’s global regulatory strategy, Dr. Tatsis also manages a worldwide team of regulatory professionals.
Prior to joining Vertex, Dr. Tatsis held positions of increasing responsibility at pharmaceutical companies such as Sanofi, Stemnion, Pfizer, and Wyeth. Most recently, she was Vice President, Head of Global Regulatory Affairs, at the Sanofi Genzyme Business Unit focused on Inflammation/Immunology, Rare Disease, Multiple Sclerosis, Ophthalmology, Neurology, and Oncology/Immuno-Oncology.
Dr. Tatsis also worked as an associate staff scientist and research fellow in Immunology and Vaccine Development at the Wistar Institute and completed a post-doctoral research fellowship in Immunology at Thomas Jefferson University. She received her Ph.D. in Cell and Molecular Biology from the University of Vermont and also holds a B.S. in Biology from Temple University.
What is Ourania Tatsis' net worth?
The estimated net worth of Ourania Tatsis is at least $25.00 million as of May 30th, 2024. Dr. Tatsis owns 53,523 shares of Vertex Pharmaceuticals stock worth more than $24,995,776 as of November 18th. This net worth approximation does not reflect any other investments that Dr. Tatsis may own. Learn More about Ourania Tatsis' net worth.
How do I contact Ourania Tatsis?
Has Ourania Tatsis been buying or selling shares of Vertex Pharmaceuticals?
Ourania Tatsis has not been actively trading shares of Vertex Pharmaceuticals during the past quarter. Most recently, Ourania Tatsis sold 2,350 shares of the business's stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $439.11, for a transaction totalling $1,031,908.50. Following the completion of the sale, the executive vice president now directly owns 53,523 shares of the company's stock, valued at $23,502,484.53. Learn More on Ourania Tatsis' trading history.
Who are Vertex Pharmaceuticals' active insiders?
Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), E. Morrey Atkinson, III (EVP), Sangeeta Bhatia (Director), Jonathan Biller (EVP), Joshua Boger (Director), Carmen Bozic (CMO), Reshma FASN (M.D.), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ian Smith (COO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vertex Pharmaceuticals?
During the last year, insiders at the pharmaceutical company sold shares 22 times. They sold a total of 79,162 shares worth more than $36,816,298.16. The most recent insider tranaction occured on August, 30th when Chairman Jeffrey M Leiden sold 3,784 shares worth more than $1,888,216.00. Insiders at Vertex Pharmaceuticals own 0.2% of the company.
Learn More about insider trades at Vertex Pharmaceuticals. Information on this page was last updated on 8/30/2024.
